RxDoctor Payments Data

Francois Dutoit, MD

Family Medicine · Lawton, OKNPI 1760477509

Payments from drug & device makers

$9,526in general payments, 2019–2025

Across 613 payments — averaging $15.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Pfizer$825
  • GSK$662
  • Novo Nordisk$634
  • AbbVie$540
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$9,28998%
  • Education$2372%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,526 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$279,430
Medicare patients
764
Services billed
9,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$121,354
Humira(Cf) PenAdalimumab14$94,978
MounjaroTirzepatide56$87,442
NuplazidPimavanserin Tartrate18$61,495
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$61,308
Synjardy XrEmpagliflozin/Metformin Hcl63$52,414
Soliqua 100-33Insulin Glargine/Lixisenatide46$51,122
OzempicSemaglutide42$49,701
BiktarvyBictegrav/Emtricit/Tenofov Ala11$46,509
JardianceEmpagliflozin58$45,005
VraylarCariprazine Hcl37$43,946
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog36$41,977
TrulicityDulaglutide28$38,199
FarxigaDapagliflozin Propanediol42$32,478
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$25,342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,100$125,64184 claims
PfizerEliquis$825$121,354133 claims
Boehringer IngelheimSynjardy Xr, Jardiance, Jentadueto Xr$363$103,397133 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$662$73,778116 claims
AbbVieVraylar, Qulipta, Linzess$540$73,57775 claims
Novo NordiskOzempic, Rybelsus$634$69,72654 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,247$57,82071 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$387$51,12246 claims
MerckJanumet Xr, Januvia$305$43,75241 claims
BayerKerendia$205$19,81911 claims
Astellas Pharma US IncMyrbetriq$151$13,82912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Lawton

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →